0001209191-18-045576.txt : 20180806 0001209191-18-045576.hdr.sgml : 20180806 20180806172148 ACCESSION NUMBER: 0001209191-18-045576 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180802 FILED AS OF DATE: 20180806 DATE AS OF CHANGE: 20180806 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 18995627 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-08-02 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP\Chief Commercial Officer Common Stock 2018-08-02 4 M 0 2125 131.89 A 48877 D Common Stock 2018-08-02 4 S 0 2125 179.00 D 46752 D Common Stock 2018-08-02 4 M 0 2155 91.05 A 48907 D Common Stock 2018-08-02 4 S 0 2155 174.59 D 46752 D Common Stock 2018-08-03 4 M 0 4250 109.14 A 51002 D Common Stock 2018-08-03 4 M 0 1553 86.52 A 52555 D Common Stock 2018-08-03 4 S 0 5803 174.20 D 46752 D Common Stock 140 I 401(k) Stock Option (Right to Buy) 131.89 2018-08-02 4 M 0 2125 0.00 D 2025-07-20 Common Stock 2125 8500 D Stock Option (Right to Buy) 91.05 2018-08-02 4 M 0 2155 0.00 D 2026-02-01 Common Stock 2155 12931 D Stock Option (Right to Buy) 109.14 2018-08-03 4 M 0 4250 0.00 D 2025-02-02 Common Stock 4250 8500 D Stock Option (Right to Buy) 86.52 2018-08-03 4 M 0 1553 0.00 D 2027-02-02 Common Stock 1553 15533 D Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1. The option vests in 16 quarterly installments from 7/21/2015. The option vests in 16 quarterly installments from 2/2/2016. The option vests in 16 quarterly installments from 2/3/2015. The option vests in 16 quarterly installments from 2/3/2017. /s/ Stephen Migausky, Attorney-in-Fact 2018-08-06